OKYO PHARMA LTD(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OKYO OKYO PHARMA LTD

Pre-Mkt 10-20 08:33:59 EDT

1.40

-0.01

-0.71%

High1.42	Low1.38	Vol24.11K
Open1.38	D1 Closing1.41	Amplitude2.84%
Mkt Cap73.47M	Tradable Cap39.26M	Total Shares52.48M
T/O33.73K	T/O Rate0.09%	Tradable Shares28.04M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OKYO","market":"US","secType":"STK","nameCN":"OKYO PHARMA LTD","latestPrice":1.4,"timestamp":1792440000000,"preClose":1.41,"halted":0,"volume":24113,"delay":0,"changeRate":-0.0070921985815602905,"floatShares":28039400,"shares":52479300,"eps":-0.24,"marketStatus":"Pre-Mkt","change":-0.01,"latestTime":"10-20 08:33:59 EDT","open":1.382,"high":1.42,"low":1.38,"amount":33726,"amplitude":0.028369,"askPrice":1.42,"askSize":150,"bidPrice":1.26,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.24,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1792503000000},"marketStatusCode":1,"adr":0,"adrRate":65,"listingDate":1652760000000,"exchange":"NASDAQ","adjPreClose":1.4,"postHourTrading":{"tag":"盘后","latestPrice":1.4,"preClose":1.4,"latestTime":"16:10 EDT","volume":2,"amount":2.82,"timestamp":1792440604800,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6542312193704994},"requestUrl":"/m/hq/s/OKYO/wiki","defaultTab":"wiki","newsList":[{"id":"2673205039","title":"Analyst Reaffirms Buy on OKYO as Urcosimod Enters Pivotal Phase 3; $5 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2673205039","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673205039?lang=en_us&edition=fundamental","pubTime":"2026-10-07 00:25","pubTimestamp":1791303939,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wainwrigh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reaffirms-buy-on-okyo-as-urcosimod-enters-pivotal-phase-3-5-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reaffirms-buy-on-okyo-as-urcosimod-enters-pivotal-phase-3-5-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673053449","title":"OKYO Pharma Enrolls First Patients in Phase 3 Neptune Trial of Urcosimod for Neuropathic Corneal Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2673053449","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673053449?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:00","pubTimestamp":1791284423,"startTime":"0","endTime":"0","summary":"OKYO Pharma enrolls first patients in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal painOKYO Pharma enrolled the first patients in its Phase 3 NEPTUNE pivotal trial of urcosimod for neuro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL4RbdcB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","SG9999014021.USD","NDAQ","LU0314104364.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","LU2210150020.SGD","BCDF","LU2095319765.USD","SG9999014005.SGD","BK4585","BK4139","OKYO","IE00BQXX3C00.GBP","SG9999014013.SGD","SG9999014039.USD","BK4112","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671421579","title":"OKYO Pharma to Present at Eyecelerator Ophthalmic Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2671421579","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671421579?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:00","pubTimestamp":1790679648,"startTime":"0","endTime":"0","summary":"OKYO Pharma to present at Eyecelerator ophthalmic conferenceOKYO Pharma will present at Eyecelerator on Oct. 8, 2026 in New Orleans.CEO Robert J. Dempsey is scheduled to speak at 1:29 p.m. CT on corne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL7DrbmP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4112","NDAQ","IE00BQXX3D17.EUR","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014039.USD","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","BK4588","IE00BN0W2V16.EUR","LU0314104364.USD","BK4585","IE00BKPKM429.USD","SG9999014021.USD","LU2210149790.SGD","BCDF","LU2095319765.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666879535","title":"OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2666879535","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666879535?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal painLONDON and NEW YORK, Sept.  09, 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358501/0/en/okyo-pharma-to-present-at-ophthalmology-futures-european-forum-and-inovation-day-at-escrs-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FET","OKYO","BK4139","BK4179","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322636","title":"OKYO Pharma Joins Cantor Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322636?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:00","pubTimestamp":1788865245,"startTime":"0","endTime":"0","summary":"OKYO Pharma joins Cantor Global Healthcare Conference fireside chatOKYO Pharma will join the Cantor Global Healthcare Conference on Sept. 9-11, 2026.A fireside chat is set for Sept. 10 at 8:35 a.m. ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL85Lc15:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00BQXX3F31.USD","NDAQ","SG9999014013.SGD","SG9999014039.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","BK4585","OKYO","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","BK4112","BCDF","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","SG9999014005.SGD","BK4139","BK4588","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662023497","title":"Piper Sandler Sticks to Its Buy Rating for OKYO Pharma Limited Sponsored ADR (OKYO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662023497","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662023497?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:56","pubTimestamp":1787831767,"startTime":"0","endTime":"0","summary":"In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on OKYO Pharma Limited Sponsored ADR, with a price target of $7.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-its-buy-rating-for-okyo-pharma-limited-sponsored-adr-okyo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-its-buy-rating-for-okyo-pharma-limited-sponsored-adr-okyo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APIE","DIVL","SAPH","OKYO","AADR","ARMH","CVY","DINT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655113318","title":"OKYO Pharma Files Form 3 for Chief Scientific Officer Rajkumar V. Patil","url":"https://stock-news.laohu8.com/highlight/detail?id=2655113318","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655113318?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:35","pubTimestamp":1785357348,"startTime":"0","endTime":"0","summary":"OKYO Pharma files Form 3 for Chief Scientific Officer Rajkumar V. PatilOKYO Pharma Chief Scientific Officer Rajkumar V. Patil reported 16,667 common shares, with stock options covering 527,032 shares ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDLbNBRrR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654004356","title":"OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2654004356","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654004356?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:00","pubTimestamp":1785236400,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, July  28, 2026  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/28/3334117/0/en/OKYO-Pharma-Announces-Purchase-of-Shares-by-Chief-Scientific-Officer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014391","title":"OKYO Pharma Joins BTIG Biotechnology Conference 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014391","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014391?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150048,"startTime":"0","endTime":"0","summary":"OKYO Pharma joins BTIG Biotechnology Conference 2026OKYO Pharma will take part in the virtual BTIG Biotechnology Conference on July 28-29, 2026.Management will hold one-on-one meetings with investors ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDLWRkSC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","SG9999014013.SGD","SG9999014039.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","BK4585","OKYO","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","BK4112","BCDF","SG9999014005.SGD","BK4139","BK4588","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654147510","title":"OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2654147510","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654147510?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:20","pubTimestamp":1785147622,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-okyo/okyo-pharma/news/okyo-pharma-nasdaqokyo-is-in-a-good-position-to-deliver-on-g","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-okyo/okyo-pharma/news/okyo-pharma-nasdaqokyo-is-in-a-good-position-to-deliver-on-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QQQJ","QQQM","QID","QQQE","TQQY","JEPQ","NDX","QQQ","QLD","QQQY","PSQ",".IXIC","QYLG","QDTE","TQQQ","IYW","ONEQ","TECS","GPIQ","NQmain","FTEC","NVIW.SI","BK4139","SQQQ","OKYO","MNQmain","QQQA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653724030","title":"OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653724030","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653724030?lang=en_us&edition=fundamental","pubTime":"2026-07-24 00:27","pubTimestamp":1784824036,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has provided an announcement. On July 23, 2026, OKYO Pharma announced that non-executive director Joh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-director-ups-stake-ahead-of-planned-phase-3-neuropathic-corneal-pain-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-director-ups-stake-ahead-of-planned-phase-3-neuropathic-corneal-pain-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CVY","SAPH","OKYO","AADR","DIVL","APIE","BK4139","ARMH","DINT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653141724","title":"Okyo Pharma director John Brancaccio acquires 5,000 shares at $1.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2653141724","media":"TIPRANKS","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653141724?lang=en_us&edition=fundamental","pubTime":"2026-07-24 00:05","pubTimestamp":1784822713,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO)announced that OKYO Pharma’s Non-Executive Director, John Brancaccio has purchased 5,000 of the Company’s ordinary shares on NASD...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-director-john-brancaccio-acquires-5000-shares-at-1-38-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-director-john-brancaccio-acquires-5000-shares-at-1-38-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653724360","title":"OKYO Pharma Director Brancaccio Raises Stake to 35,201 Shares After $1.48 Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2653724360","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653724360?lang=en_us&edition=fundamental","pubTime":"2026-07-24 00:00","pubTimestamp":1784822428,"startTime":"0","endTime":"0","summary":"OKYO Pharma director Brancaccio raises stake to 35,201 shares after $1.48 purchaseOKYO Pharma non-executive director John Brancaccio bought 5,000 ordinary shares on Nasdaq at $ 1.48 each.The purchase ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDLbZjtdS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4112","SG9999014005.SGD","LU2095319765.USD","BCDF","IE00BN0W2T93.GBP","LU2210149790.SGD","SG9999014013.SGD","LU0314104364.USD","SG9999014021.USD","BK4585","BK4139","IE00B3QW5Z07.USD","OKYO","NDAQ","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","IE00BKPKM429.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653764863","title":"Okyo Pharma says Chairman Gabriele Cerrone buys 22,500 shares at $1.45/share","url":"https://stock-news.laohu8.com/highlight/detail?id=2653764863","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653764863?lang=en_us&edition=fundamental","pubTime":"2026-07-23 00:05","pubTimestamp":1784736313,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO) announced that its Chairman, Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-says-chairman-gabriele-cerrone-buys-22500-shares-at-1-45-share-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-says-chairman-gabriele-cerrone-buys-22500-shares-at-1-45-share-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653766927","title":"OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653766927","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653766927?lang=en_us&edition=fundamental","pubTime":"2026-07-22 22:27","pubTimestamp":1784730433,"startTime":"0","endTime":"0","summary":"An update from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. OKYO Pharma Limited is a clinical-stage biopharmaceutical company fo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-executive-boosts-shareholding-ahead-of-planned-phase-3-ncp-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-executive-boosts-shareholding-ahead-of-planned-phase-3-ncp-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO","BK4139","CVY","AADR","APIE","DIVL","DINT","ARMH","SAPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653664765","title":"OKYO Pharma CDO Jacob Lifts Stake to 112,420 Shares with 3,500-share Buy at $1.4","url":"https://stock-news.laohu8.com/highlight/detail?id=2653664765","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653664765?lang=en_us&edition=fundamental","pubTime":"2026-07-22 22:00","pubTimestamp":1784728819,"startTime":"0","endTime":"0","summary":"OKYO Pharma CDO Jacob lifts stake to 112,420 shares with 3,500-share buy at $1.4OKYO Pharma Chief Development Officer and Director Gary S. Jacob bought 3,500 ordinary shares at $1.4 each.The purchase ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL79lzpj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014021.USD","BCDF","BK4588","IE00BKPKM429.USD","NDAQ","OKYO","SG9999014013.SGD","BK4585","IE00BN0W2W23.USD","LU2210150020.SGD","LU2210149790.SGD","SG9999014039.USD","BK4139","BK4112","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653024769","title":"OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2653024769","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653024769?lang=en_us&edition=fundamental","pubTime":"2026-07-22 22:00","pubTimestamp":1784728800,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, July  22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/22/3331510/0/en/OKYO-Pharma-Announces-Purchase-of-Shares-by-Chief-Development-Officer-and-Director.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653878203","title":"OKYO Pharma to Present Ophthalmology Pipeline Ahead of Phase 3 Urcosimod Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653878203","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653878203?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:30","pubTimestamp":1784640611,"startTime":"0","endTime":"0","summary":"An update from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. On July 21, 2026, OKYO Pharma announced it will present at the H.C. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-to-present-ophthalmology-pipeline-ahead-of-phase-3-urcosimod-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-to-present-ophthalmology-pipeline-ahead-of-phase-3-urcosimod-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SAPH","DINT","DIVL","ARMH","OKYO","CVY","APIE","AADR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653208954","title":"Okyo Pharma Says Chairman Gabriele Cerrone Boosts Stake to 20.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653208954","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653208954?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:15","pubTimestamp":1784639732,"startTime":"0","endTime":"0","summary":"Okyo Pharma  chairman Gabriele Cerrone has increased his stake in the clinical-stage company to 10.9 million shares, or 20.5% of the company's issued shares, with the purchase of 25,000 ordinary shares at $1.40 per share, the company said Tuesday.The purchase was made through Panetta Partners, an entity in which Cerrone has a beneficial interest, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653270059","title":"OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2653270059","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653270059?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:00","pubTimestamp":1784638800,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, July  21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/21/3330501/0/en/OKYO-Pharma-to-Present-at-the-H-C-Wainwright-6th-Annual-Ophthalmology-Virtual-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.okyopharma.com","stockEarnings":[{"period":"1week","weight":-0.0278},{"period":"1month","weight":0.0294},{"period":"3month","weight":-0.0278},{"period":"6month","weight":-0.1358},{"period":"1year","weight":-0.375},{"period":"ytd","weight":-0.3237}],"compareEarnings":[{"period":"1week","weight":-0.0149},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.0243},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.1537},{"period":"ytd","weight":0.124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.016922},{"month":2,"riseRate":0.25,"avgChangeRate":-0.048425},{"month":3,"riseRate":0.5,"avgChangeRate":-0.0442},{"month":4,"riseRate":0.5,"avgChangeRate":-0.006578},{"month":5,"riseRate":0.75,"avgChangeRate":0.124495},{"month":6,"riseRate":0.4,"avgChangeRate":-0.035766},{"month":7,"riseRate":1,"avgChangeRate":0.191153},{"month":8,"riseRate":0.4,"avgChangeRate":-0.011918},{"month":9,"riseRate":0.2,"avgChangeRate":-0.1052},{"month":10,"riseRate":0.6,"avgChangeRate":0.07451},{"month":11,"riseRate":0,"avgChangeRate":-0.142327},{"month":12,"riseRate":0.75,"avgChangeRate":0.059341}],"exchange":"NASDAQ","name":"OKYO PHARMA LTD","nameEN":"OKYO PHARMA LTD","securityTypeName":"DR","adrRate":"1:65"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OKYO PHARMA LTD(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OKYO PHARMA LTD(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OKYO PHARMA LTD,OKYO,OKYO PHARMA LTD股票,OKYO PHARMA LTD股票老虎,OKYO PHARMA LTD股票老虎国际,OKYO PHARMA LTD行情,OKYO PHARMA LTD股票行情,OKYO PHARMA LTD股价,OKYO PHARMA LTD股市,OKYO PHARMA LTD股票价格,OKYO PHARMA LTD股票交易,OKYO PHARMA LTD股票购买,OKYO PHARMA LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OKYO PHARMA LTD(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OKYO PHARMA LTD(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction